Actively Recruiting
Evaluating Weekly Versus Alternative Dosing of Ficerafusp Alfa with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Led by Bicara Therapeutics · Updated on 2026-10-13
160
Participants Needed
7
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of ficerafusp alfa, a drug targeting EGFR and TGF-beta, combined with pembrolizumab, for adults with recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma HNSCC. The goal is to compare the antitumor activity of an alternative dosing schedule of ficerafusp alfa against the standard weekly dosing, aiming to find a comparable treatment option for this cancer type. Participants initially receive a loading phase treatment of ficerafusp alfa 1500 mg once weekly with pembrolizumab 200 mg every three weeks for 12 weeks. Those without disease progression then enter a maintenance phase where they are randomly assigned to either an alternative dose of ficerafusp alfa 2250 mg every three weeks with pembrolizumab or continue the standard weekly ficerafusp alfa dose with pembrolizumab every three weeks. During the study, participants undergo regular assessments including imaging reviews based on RECIST 1.1 criteria to monitor tumor response and progression. Researchers measure outcomes such as progression-free survival, response rates, overall survival, and adverse events over periods ranging from 9 months to 3 years. Safety monitoring continues up to 90 days after treatment ends, with the overall study duration lasting until March 2029.
CONDITIONS
Brief Title
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Research Team
M
Medical Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here